Sara Tolaney, SABCS 2022: Adjuvant paclitaxel and trastuzumab for node-negative HER2+ breast cancer

The APT trial (NCT00542451) was a phase 3, single-arm, multicenter, investigator-initiated trial investigating adjuvant paclitaxel and trastuzumab in patients with small (≤3 cm), node negative HER2+ breast cancer.
In this interview with Dr Sara Tolaney (Harvard Medical School, Boston, MA, USA) we discuss the end-of-study, 10-year survival outcome results and explore what the study has demonstrated in terms of the role of the HER2DX genomic assay in predicting long-term outcomes.
The abstract entitled ‘Adjuvant Paclitaxel and Trastuzumab Trial (APT) for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Breast Cancer: final 10-year analysis’ was presented at San Antonio Breast Cancer Symposium (SABCS), 06-10, December, 2022.
Questions:
1. What are the unmet needs in the treatment of women with node negative HER2+ breast cancer? (0:10)
2. What did the APT trial teach us about the efficacy and safety of adjuvant paclitaxel and trastuzumab in this indication? (1:13)
3. How useful was the HER2DX genomic assay in assessing the risk of recurrence? (3:02)
4. What are your key take-home messages from this study? (5.41)
Disclosures: Sara Tolaney is a consultant for Novartis, Pfizer, Merck, Eli Lilly, AstraZeneca, Genentech/Roche, Eisai, Sanofi, Bristol Myers Squibb, Seattle Genetics, Odonate Therapeutics, CytomX Therapeutics, Daiichi Sankyo, Athenex, Gilead, Mersana, Certara, Ellipses Pharma, 4D Pharma, OncoSec Medical Inc., BeyondSpring Pharmaceuticals, OncXerna, Zymeworks, Zentalis, Blueprint Medicines, Reveal Genomics, ARC Therapeutics, Infinity Therapeutics, Chugai Pharmaceuticals, Myovant, Zetagen, Umoja Biopharma, Menarini/Stemline, Aadi Biopharma and Bayer and discloses grant/research support from Genentech/Roche, Merck, Exelixis, Pfizer, Lilly, Novartis, Bristol Myers Squibb, Eisai, AstraZeneca, NanoString Technologies, Cyclacel, Nektar, Gilead, Sanofi and Seattle Genetics.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Gina Furnival